Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Lung Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 38Nivolumab 24atezolizumab 10Ipilimumab 7Carboplatin 6avelumab 5Paclitaxel 5Magnetic Resonance Spectroscopy 5Docetaxel 5Cyclophosphamide 5fludarabine 4cabozantinib 4Specimen Handling 4Pemetrexed 4regorafenib 3Interleukin-2 3Gemcitabine 3130-nm albumin-bound paclitaxel 3spartalizumab 2lenvatinib 2epacadostat 2durvalumab 2aldesleukin 2Taxes 2Immune Checkpoint Inhibitors 2Cisplatin 2Biopsy 2Albumin-Bound Paclitaxel 2zanidatamab 1veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × devimistat × Thoracic × Clear all
NCT05733000 2023-03-10

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Northwestern University

Phase 2 Recruiting
94 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡